Personalized Neoantigen Vaccine plus Regorafenib Increases Rgs2⁺CD8⁺ T Cells Infiltration and Reprograms the Tumor Microenvironment in Microsatellite Stable Colorectal Cancer Liver Metastases

Abstract excerpt

Microsatellite stable colorectal cancer liver metastases (MSS-CRLM) resist immune checkpoint inhibitors due to their immunosuppressive tumor microenvironment (TME) and low mutation burden (TMB). A personalized neoantigen vaccine, Neo-CRCVAS, using whole-exome and RNA sequencing of murine MSS-CRC cells, comprising 7 immunogenic neoantigen peptides with Poly(I:C) is developed and combined with regorafenib as a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to CAR-T cell therapy research
• Share to Immunotherapy and Immune Responses